Bio Spectrum Magazine - BioSpectrum India September 2023
Bio Spectrum Magazine - BioSpectrum India September 2023
Go Unlimited with Magzter GOLD
Read Bio Spectrum along with 8,000+ other magazines & newspapers with just one subscription View catalog
1 Month $9.99
Subscribe only to Bio Spectrum
In this issue
Will 3D Bioprinting Turn Disruptor in Healthcare?
3D bioprinting has come to the limelight recently and a lot of research activities have been undertaken for the same. Creating organ models that can be used for preclinical testing of drugs and other interventional molecules and creating organ scaffolds for clinical transplantation can become a breakthrough in the healthcare domain. Though the technology is yet to be accepted fully among India’s medical sector, current efforts by academics and research labs will ensure that 3D bioprinting provides personalised solutions for individual patients.
How Tech Innovations Impact Cardiac Care
Cardiac care has seen a transformation over the years with technology playing an important role. Armed with Artificial intelligence (AI) and machine learning (ML), cardiac care providers, with the right technology, have received the right impetus to revolutionise treatment mechanisms. Let us delve into the new technologies which the industry is offering to mankind and decipher the way forward.
Mynvax Offers ‘Warm Vaccine' For COVID-19
Biotech startup Mynvax, incubated at the Indian Institute of Science (IISc) in Bengaluru, has developed heat-tolerant COVID-19 vaccine formulations.
“R&D outsourcing has become a ‘must have' than ‘good-to have' strategy”
Aragen Life Sciences (formerly GVK BIO), a leading contract research and development organisation headquartered in Hyderabad, is marking its transition to a new brand identity in its 20th year. Established in 2001, the company is poised for growth in the outsourced discovery, development, and manufacturing services sector across both large and small molecule platforms with new investments and collaborations. In conversation with BioSpectrum, Manni Kantipudi, Chief Executive Officer, Aragen Life Sciences, Hyderabad reveals more about the company’s recent rebranding and growth plans. Edited excerpts;
Premas Biotech to commercialise VLP vaccine tech against Delta variant
Gurugram-based Premas Biotech has signed a licensing deal with Oravax Medical for the development and commercialisation of its virus-like-particle COVID-19 vaccine technology.
SARS-CoV-2: A Biochemical Treatise on its Past, Present & Future
The SARS-CoV-2 pandemic is unprecedented but equally unprecedented is the contribution of scientists who have helped us in understanding the mechanisms by which it infects human beings and also, developing a variety of vaccines to protect the masses, in a year’s time, which can be called truly groundbreaking. This article gives an overview of the progress made by scientists around the world working round the clock in developing an understanding of the SARS-CoV-2 evolution and COVID-19 disease pathogenesis, and also makes an attempt to suggest the possible ways of coping with this pandemic if we have to co-exist with it forever!
Merck launches Pergoveris Pen for fertility treatment in India
Merck Specialties, the healthcare business of Merck in India, has launched Pergoveris Pen for advanced infertility treatment in India.
GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B
While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry.
Glenmark ties up with SaNOtize to commercialise COVID-19 nasal spray
Mumbai-based Glenmark Pharmaceuticals and Canadian biotech firm SaNOtize Research & Development Corporation
CEPI prioritises Rift Valley fever vax
Sep 01, Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) has signed an implementing partner agreement with Integrum Scientific (US) as part of its ongoing efforts to combat Rift Valley fever (RVF)—one of its priority diseases with epidemic potential.
3D printing moulds healthcare innovations
Pharmaceuticals, bio-medicine, aviation, and automobiles industries have rapidly adopted 3D printing over the years, worldwide, to develop new solutions and prototypes. It is also helping many industries, healthcare, in particular, increase productivity. Despite all its advantages, 3D printing technology is currently posing a number of challenges in the market such as initial costs, limitation to the metals and plastics used for 3D printing, lack of policy standardisation, etc.
WHO Updates Guidelines For TB Detection
The World Health Organization (WHO) has issued an update to its consolidated guidelines on the detection of tuberculosis (TB) and drug-resistant TB.
Is The 5G Health Scare Unfounded?
The introduction of the 5G network has been mired in numerous controversies. Governments across the globe, activists and telecom operators are embroiled in a bitter fight, filing lawsuits and protesting in large numbers. Although most of the available research on electromagnetic fields (EMF) reveals that there are no harmful effects from mobile radiation, some studies do reveal that it has the potential to damage the very structure of the DNA. Cancer, impaired reproductive health and numerous other disorders, including psychiatric, have been attributed to 5G. Will the implementation of the 5G network have serious health implications, or are these fears unfounded? We try to weigh-in the opposing sides.
Is Antibody Cocktail Offering The Right Mix?
Although the clinical outcomes, as well as clinical trials, have been very promising for patients treated with the antibody cocktail so far, the Delta plus variant is considered to be resistant to the monoclonal antibody (mAb) cocktail treatment.
“Our allergic rhinitis drug is technologically superior, masks bitterness and 52% cheaper”
Alok Malik, Group Vice President & Head, India Formulations, Glenmark Pharmaceuticals, Mumbai
Techade REDEFINING FUTURE OF life sciences industry
Digital transformation is the topmost priority for global corporations and in a highly connected world that will remain largely contactless for an extended period, there are shifts in business models, customer experience, operations, and employee experience. With technology adoption accelerating across sectors, 2021 is likely to put the spotlight on the emergence of growth verticals in the life sciences sector namely healthcare, pharma, medical devices, diagnostics etc. India is now standing at the cusp of a re-imagined decade of technology, commonly being referred to as ‘Techade’. While we anticipate a significantly better global economic growth this year as compared to 2020, we are also very much looking forward to the enhancement being brought to the Indian life sciences industry as it continues its transformation journey in this redefined techade.
Multifarious Cataract cures emerge
Being documented as India’s most significant cause of bilateral blindness that is for both eyes, cataract has become an economic and social burden that is increasing with the ageing population.
Zydus Introduces New Feature In Drug Packaging To Avoid Counterfeiting
Zydus Cadila has introduced a new feature called Zydus Verify in the packaging of its critical drugs to help patients ensure that the product is not fake or counterfeited.
Malaria, Dengue TB Play Second Fiddle To Covid - 19
Although India has worked relentlessly towards developing innovative testing solutions for COVID-19 throughout last year, the timely detection of a number of other infectious diseases has been sidelined. In India, the range and burden of infectious diseases such as tuberculosis, malaria, filariasis, leprosy, HIV infection, typhoid, hepatitis etc., are enormous. In fact, inadequate containment of the vector has resulted in recurrent outbreaks of dengue fever and re-emergence of chikungunya virus disease and typhus fever. If India can develop more than 20 different diagnostic tests or devices in a single year to fight COVID-19, many more such innovations can be brought to effectively detect other infections looming in our country.
Pandemic Sets New Benchmarks For Early-Stage Healthcare Startups
The COVID-19 pandemic has been an enabler of this change as care-delivery models had to be quickly revamped to address two concerns – the diseases and the impacts of the virus on the treatment of other diseases. We aim to assess the qualitative and quantitative impact of COVID-19 and other macroeconomic events on the startup ecosystem over the last few years and try to understand the implications for the future.
Stride Ventures leads Rs 25 Cr debt round in MediBuddy
Stride Ventures, one of India’s leading venture debt funds, has led a debt round of Rs 25 crore in Bengaluru-based startup MediBuddy that helps its users consult specialist doctors, order medicines and book lab tests from the comfort of their homes.
‘‘We see growing interest of healthcare testing labs, Pharmaceutical QC and R&D labs in implementing next-gen lab automation solutions''
US-based Abbott Informatics, formerly known as STARLIMS, is one of the companies with a long and established presence in the space of lab automation. Taking pride in offering the world class technological solutions, the company has recently announced the launch of STARLIMS Quality Manufacturing Solution QM12.2 which is built on the latest STARLIMS Technology V12 platform, along with STARLIMS SDMS (Scientific Data Management System) V12.2. To find out more about the company’s automated offerings in India, BioSpectrum spoke to Pradeep Nagisetty, Regional Sales Manager - India & Sub Continent, Abbott Informatics - STARLIMS, Hyderabad.
‘Juvenile Idiopathic Arthritis' remains a puzzle
LET'S TALK HEALTH & SCIENCE
India proposes BRICS Consortium to tackle NCDs as flagship programme
Experts deliberated on emerging issues in the various fields of Biotechnology and Biomedicine at the fourth BRICS Working Group meeting on the subject area.
LAB AUTOMATION - TRAVAILS IN INDIA
Whether it is the industry or academia, life sciences workers are gradually accepting the fact that lab data digitisation improves processes, simplifies workflows and makes research and development (R&D) more efficient. With increasing advances in machine learning (ML) and artificial intelligence (AI), digitisation in the research environment is set to become an integral part of every laboratory worldwide. But in emerging markets such as India, there are a large number of factors responsible for its slow adoption such as lack of skilled workforce, high maintenance and service costs, limited expertise, data security etc.
Govt pays Biological E Rs 1500 Cr for 30 Cr vaccines
Union Ministry of Health has finalised arrangements with Hyderabad-based vaccine manufacturer Biological E to reserve 30 crores of COVID-19 vaccine doses.
Biological E, Canadian firm to jointly manufacture mRNA vaccines in India
Canadian firm Providence Therapeutics Holdings Inc. and Hyderabad-based Biological E have announced the execution of a term sheet that sets forth the material terms for a definitive licensing and collaboration agreement.
BDR Pharma launches affordable drug to treat ovarian, prostate cancers
Mumbai-based BDR Pharmaceutical has launched BDPARIB (RUCAPARIB) to treat advanced ovarian and prostate cancers
Wipro Focuses On Transforming Vaccine Safety Assessment
Bengaluru -based IT firm Wipro has announced a partnership with Hyderabad-based Transcell Oncologics to transform vaccine safety assessment using augmented intelligence (AI).
Dr. Reddy's Launches Sputnik V Vaccine In India
Dr. Reddy’s Laboratories announced that the first consignment of imported doses of the Sputnik V vaccine that landed in India on May 1, 2021, received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13, 2021. As part of a limited pilot, the soft launch of the vaccine has commenced and the first dose of the vaccine was administered in Hyderabad on May 14, 2021.
Rare diseases policy outlines challenges sans solutions
There is no substantial data on the number of people suffering from rare diseases in India and the data that is available is from tertiary care hospitals. The lack of epidemiological data on rare diseases makes it a herculean task to determine the prevalence and burden of rare diseases, hence hampering the definition of rare diseases in the Indian context.
Bio Spectrum Magazine Description:
Publisher: MM Activ Sci-Tech Communication
India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.
- Cancel Anytime [ No Commitments ]
- Digital Only